IE 11 is not supported. For an optimal experience visit our site on another browser.

CombiMatrix Corporation to Release First Quarter Financial Results on May 11, 2011

IRVINE, Calif., May 4, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its first quarter 2011 financial results on Wednesday, May 11, 2011. Results will be released at the close of trading on that day. 
/ Source: GlobeNewswire

IRVINE, Calif., May 4, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its first quarter 2011 financial results on Wednesday, May 11, 2011. Results will be released at the close of trading on that day. 

A conference call has also been scheduled regarding CombiMatrix Corporation's first quarter 2011 financial results. The presentation and Q&A session will start at 1:30 p.m. Pacific Time (4:30 p.m. Eastern) on May 11, 2011.

To attend the presentation by phone, dial 1-888-857-6932 for domestic callers and 1-719-457-2657 for direct dial or international callers. To listen to the call via CombiMatrix's website, go to , in the Investor/Events section, ().

A replay of the presentation will be available for 14 days, either via the CombiMatrix website Investor/Events section () or by dialing 1-877-870-5176 for domestic callers or 1-858-384-5517 for direct dial international callers. When prompted, enter playback pin number 5318506.

The call will also be webcast live and can be accessed at CombiMatrix's website at , in the Investor/Events section, ().

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Diagnostics, is a CAP/CLIA certified molecular diagnostics laboratory offering comprehensive profiling of chromosomes and genes for oncology, pediatric, and reproductive disorders. CombiMatrix Diagnostics offers a comprehensive and proprietary analysis of cancer tumors at the DNA, or molecular level. CombiMatrix was the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. CombiMatrix also offers pediatric and reproductive testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. Additional information about CombiMatrix Corporation is available at . Additional information about CMDX is available at or by calling 1-800-710-0624.

CONTACT: Company Contact: R. Judd Jessup President & CEO, CombiMatrix Corporation Tel (949) 753-0624 Investor Relations Contact: Matthew H. Clawson Partner, Allen & Caron, Inc. Tel (949) 474-4300 matt@allencaron.com